Stay updated with breaking news from Oche. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Swiss multinational healthcare company, Roche, has terminated its worldwide license and collaboration agreement with Repare Therapeutics despite the company earning a $40 million milestone payment from Roche.
LONDON/FRANKFURT (Reuters) -Roche forecast a pick up in sales growth this year as it overcomes a slump in demand for its COVID-19 products and a decline in sales of a trio of established cancer drugs abates. Sales in 2023 rose 1% to 58.7 billion Swiss francs ($68 billion), slightly below analysts' average estimate of closer to 60 billion francs, according to LSEG data. CEO Thomas Schinecker told reporters it was a "significant achievement" that the company increased sales despite the sharp drop in demand for its COVID therapy and diagnostics kits.
Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry vision Up to 60% of people receiving Vabysmo were able to...
Swiss pharmaceutical company Roche announced net income was down but it expects mid single-digit sales increase for 2024. Roche reported that its International Financial Reporting Standards (IFRS) net income for fiscal year 2023 declined about 9% to 12.36 billion Swiss francs from 13.53 billion francs last year. But IFRS net income increased by 7% at constant exchange rates (CER) due to the increase in operating profit and lower income tax expenses. Core earnings per share was 18.57 francs down
Chemed Co. (NYSE:CHE – Get Free Report) was the recipient of a significant drop in short interest in the month of January. As of January 15th, there was short interest totalling 422,500 shares, a drop of 6.3% from the December 31st total of 450,900 shares. Based on an average trading volume of 78,200 shares, the […]